Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (NasdaqGS: TMCI) is a medical technology company focused on advancing the surgical management of bunion and related midfoot deformities. As a commercial‑stage orthopaedic device company with a portfolio centered on 3D bunion correction, Treace regularly issues news on product innovation, clinical evidence, financial performance and capital structure.
On this page, readers can follow TMCI news covering quarterly and annual financial results, revenue trends, liquidity updates and guidance changes, as reported in the company’s earnings releases and related Form 8‑K filings. These updates often discuss factors such as surgeon adoption of Treace’s expanded bunion technology portfolio, procedure volume dynamics and the impact of broader economic conditions on elective bunion surgery.
Treace also announces new technologies and product milestones, including developments in its Lapiplasty 3D Bunion Correction System, minimally invasive systems such as Nanoplasty and Percuplasty, the SpeedMTP MTP Fusion System, SpeedPlate rapid compression implants and IntelliGuide patient specific planning and cut guide technology. News items may highlight first surgical cases with new platforms, transitions from limited market release to full market release and surgeon feedback on workflow and clinical use.
In addition, TMCI news includes updates on clinical studies like ALIGN3D and MTA3D, where interim data on radiographic correction, recurrence, pain and patient‑reported outcomes are presented at orthopedic conferences. Investors can also see announcements about debt financing arrangements, investor conferences, investor days and changes in board composition or governance roles.
For investors, clinicians and analysts tracking TMCI stock, this news feed offers a consolidated view of Treace’s financial disclosures, product pipeline developments and market‑facing activities related to bunion and midfoot deformity surgery.
Treace Medical Concepts (TMCI) announced positive interim results from the ALIGN3D clinical study at the ACFAS Annual Scientific Conference. The study evaluated 128 participants undergoing the Lapiplasty 3D Bunion Correction procedure. Key findings include an early weight-bearing average of 8.3 days, a 1.4% recurrence rate at 12 months, and significant improvements in patient-reported pain and quality of life. The study aims to assess long-term outcomes and has completed enrollment, with final results expected in 2023.
Treace Medical Concepts (TMCI) announced it will release its Q1 2021 financial results on May 25, 2021, after market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Investors can access the call by dialing (833) 730-3977 (domestic) or (720) 405-2122 (international) with Conference ID: 1157038. The company specializes in surgical treatments for bunions through its patented Lapiplasty® 3D Bunion Correction™ system, aimed at enhancing patient recovery and addressing the root causes of bunion deformities.
Treace Medical Concepts (TMCI) announced that interim results of its ALIGN3D™ clinical study will be presented at the ACFAS Scientific Conference on May 19, 2021. The study evaluates the effectiveness of the Lapiplasty® 3D Bunion Correction™ in treating hallux valgus, involving 173 patients across seven sites. Key endpoints include recurrence of the bunion deformity and patient-reported outcomes after two years. The final follow-up for primary endpoints is expected in the first half of 2023, indicating ongoing commitment to advancing surgical treatment standards.
Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced its upsized initial public offering pricing of 11,250,000 shares at $17.00 each, aiming for gross proceeds of approximately $106.3 million. Of these shares, 6,250,000 will be sold by Treace, while 5,000,000 are from selling stockholders. Additionally, underwriters have a 30-day option to purchase up to 1,687,500 additional shares. Trading is set to commence on April 23, 2021, with the closing expected by April 27, 2021, following standard conditions.
Treace Medical Concepts (Nasdaq: TMCI) announced an upsized initial public offering (IPO) of 11,250,000 shares, priced at $17.00 each, aiming to raise approximately $106.3 million before expenses. Of these, 6,250,000 shares are offered by Treace while 5,000,000 shares are from selling stockholders. The offering includes a 30-day option for underwriters to purchase an additional 1,687,500 shares. Trading on the Nasdaq is set to start on April 23, 2021, with the closing anticipated on April 27, 2021, pending customary conditions.